Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

376 results about "De ubiquitination" patented technology

Heterobifunctional compounds for the degradation of KRAS protein

PCT designated stage expiredWO2025006753A2Organic active ingredientsOrganic chemistryViral OncogeneRat sarcoma virus
The invention provides compounds that degrade the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein including mutant forms via the ubiquitination of the KRAS protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
Owner:MERCK PATENT GMBH +2

Heterobifunctional compounds for the degradation of kras

PCT designated stage expiredWO2025006783A2Organic active ingredientsOrganic chemistryViral OncogeneRat sarcoma virus
The invention provides compounds that degrade the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein including mutant forms via the ubiquitination of the KRAS protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
Owner:ANDERSON COREY DON +3

Salt forms of IRAK4 degraders

PCT designated stage expiredWO2025080300A1AntipyreticAnalgesicsDiseaseReceptor
The present disclosure relates generally to various salt forms and compositions thereof useful for the modulation of interleukin-1 receptor-associated kinase 4 ("IRAK4") via ubiquitination and / or degradation and uses of the same in the treatment various diseases.
Owner:KYMERA THERAPEUTICS INC

Protein targeted degradation system capable of being regulated and controlled in programmable mode, construction and application of protein targeted degradation system

ActiveCN119495366AEfficient degradationPrecise regulation of degradationProteomicsGenomicsProtein targetDanoprevir
The invention discloses a modified Trim 21 (delta Trim 21)-based target protein degradation control system, which takes a modified protein delta Trim 21 degradation system as a basis, takes blue light, abscisic acid, Danoprevir and / or MK-5172 as inductors, controls the combination of target protein and delta Trim 21 by introducing and modifying a controllable protein dimerization system on the basis of the modified protein delta Trim 21 degradation system, and improves the target protein degradation control system. The protein targeted degradation capable of being modularly regulated and controlled is carried out. Two regulation and control modules, namely a target protein recognition module and a degradation module based on E3 ubiquitinase, are constructed by splitting and recombining a controllable protein dimerization system and a delta Trim 21 structural domain. The invention also discloses a degradation device comprising the system. The invention also discloses a method for accurately regulating endogenous proteins (degradation of proteins related to tumorigenesis) by using the programmable regulation type modular protein degradation device, so as to achieve the effect of specifically killing tumors. The invention also provides a eukaryotic expression vector and a regulation method of the programmable regulation type protein targeted degradation device.
Owner:EAST CHINA NORMAL UNIV

GPX4 protein degradation agent and application

According to the GPX4 protein degradation agent and the application, the degradation agent serves as molecular glue to induce tumor cell ferroptosis and is different from an existing PROTAC technology, and the molecular glue can induce interaction between E3 ubiquitin ligase and target protein GPX4 and promote ubiquitination of the E3 ubiquitin ligase and the target protein GPX4. Compared with the existing GPX4 degradation agent, the molecular glue has the advantages of small molecular weight, high cell permeability and better druggability. The GPX4 molecular glue disclosed by the invention can be used for effectively degrading GPX4 and has a killing effect on various tumor cell lines. The preparation method is simple in synthesis route and mild in reaction condition, can be used for being developed into a new generation of GPX4 targeting drugs, and has great clinical application value and considerable market potential.
Owner:INSTITUTE OF BASIC MEDICINE & CANCER CHINESE ACADEMY OF SCIENCES (PREPARATORY)

NSD protein degradation agent and application thereof

The invention provides an NSD protein degradation agent and application thereof, and particularly provides a compound with a structure as shown in a formula (I) or pharmaceutically acceptable salt thereof, or a stereoisomer or a prodrug molecule thereof. The compound can degrade proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, GSPT1 and the like in a targeted ubiquitination manner, so that the compound can be used for treating indications related to abnormal expression of the proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, GSPT1 and the like. # imgabs0 #
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI +2

Medicine for treating renal cell carcinoma and application thereof

The invention discloses a medicine for treating renal cell carcinoma and application thereof, and belongs to the field of biomedicine, the medicine comprises a reagent capable of ubiquitination degradation of WEE1, FBXO2 overexpression can prevent proliferation and movement of renal cell carcinoma cells, and FBXO2 can reduce abundance of WEE1 through ubiquitination degradation; the interaction and ubiquitination degradation of the WEE1 are mediated by the FBA structural domain of the FBXO2; fBXO2 degrades WEE1 through ubiquitination to inhibit RCC canceration.
Owner:GENERAL HOSPITAL OF NUCLEAR IND

Bifunctional compounds for androgen receptor degradation and methods of use

Disclosed herein are androgen receptor modulators, bifunctional compounds comprising these compounds, pharmaceutical compositions thereof and method for the treatment of androgen receptor-mediated disorders or diseases, wherein the bifunctional compounds are useful for modifying the ubiquitination and subsequent degradation of target polypeptides and proteins, in particular, androgen receptor.
Owner:ETERN THERAPEUTICS (WUXI) CO LTD

Application of therapeutic target to preparation of medicine for resisting cancer cell cis-platinum resistance

The invention discloses application of a therapeutic target to preparation of a drug for resisting cancer cell cis-platinum resistance. The therapeutic target is NPR1; the NPR1 is used for inhibiting mitochondrial autophagy-dependent ferroptosis by inhibiting the ubiquitination degradation level of PARL. The invention discloses a therapeutic target NPR1 and an NPR1-MARCH8-PARL axis, expression of PARL can be down-regulated by blocking or inhibiting the NPR1 or NPR1-MARCH8-PARL axis, and a mitochondrial autophagy-dependent ferroptosis process can be recovered, so that drug resistance of gastric cancer cells is inhibited, and a new method is further provided for preparing drugs for resisting cisplatin drug resistance of the gastric cancer cells.
Owner:THE FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE (YIJISHAN HOSPITAL OF WANNAN MEDICAL COLLEGE)

Polypeptide-based PROTAC condensation body and preparation method and application thereof

The invention discloses a polypeptide-based PROTAC condensation body as well as a preparation method and application of the polypeptide-based PROTAC condensation body. The polypeptide-based PROTAC aggregate comprises an HER2 (human epidermal growth factor receptor) targeting module, an EGFR (epidermal growth factor receptor) targeting module, a VHL E3 ligase targeting module and a self-assembly module. The polypeptide-based PROTAC condensation body can dynamically enrich E3 ligase VHL and promote efficient ubiquitination degradation of HER2, EGFR and downstream signal channel protein of HER2 and EGFR, the degradation efficiency of HER2 and EGFR protein can reach 92%, the degradation efficiency of downstream signal channel protein such as SOS2 and RAS can reach 80%, and in addition, the polypeptide-based PROTAC condensation body has the advantages that the polypeptide-based PROTAC condensation body can be used as an efficient ubiquitination condensation body; the polypeptide-based PROTAC condensation body has the characteristics of tumor targeting and long-acting retention, and dose-dependent tumor specific accumulation and retention can be realized through in-situ self-assembly.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA

NSD protein degradation agent and use thereof

The present invention provides an NSD protein degradation agent and a use thereof. Specifically, the present invention provides a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer or prodrug molecule thereof. The compound can degrade proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, and GSPT1 via target ubiquitination, and therefore can be used to treat indications related to abnormal expression of proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, and GSPT1.
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI +2

MRNA vaccine based on protein degradation technology

The invention relates to the technical field of biological medicine, in particular to an mRNA vaccine based on a protein degradation technology. The mRNA vaccine comprises an mRNA system and a lipid nanoparticle. The mRNA system refers to two mRNAs which can respectively encode an antigen-docking module and a recognition module-E3 ubiquitin ligase binding domain, the E3 ubiquitin ligase binding domain recruits an E3 ubiquitin ligase complex, the antigen is ubiquitinated and degraded into a peptide fragment by utilizing specific binding between the recognition module and the docking module, the peptide fragment is recognized by an MHC-I complex, and the E3 ubiquitin ligase binding domain is used for identifying the MHC-I complex. Then, the body immunity is activated, and the anti-tumor effect is realized. Besides, the invention provides a universal mRNA vaccine, that is, theoretically, different diseases can be treated only by replacing antigens in an mRNA system, the research and development time of the vaccine is greatly shortened, the research and development cost is reduced, a new thought is provided for tumor treatment, and the mRNA vaccine has a huge application prospect.
Owner:ZHEJIANG UNIV OF TECH +1

Novel compound for degradation of target protein or polypeptide by polyubiquitination

Provided are a compound capable of degrading a target protein using ubiquitin and having a targeted protein binding moiety (TBM) structure binding to a target protein or polypeptide and a ubiquitin binding moiety (UBM) structure to which ubiquitin is bound, wherein the compound can be induced to polyubiquitination by the UBM structure present in the compound, and thus have an advantage of becoming a protein degrader capable of degrading a target protein or polypeptide.
Owner:PRAZERTHERAPEUTICS INC

OsRbohB gene, OsRbohB gene mutant and application of OsRbohB gene mutant

The invention relates to the technical field of plant genetic engineering, in particular to an OsRbohB gene, an OsRbohB gene mutant and application of the OsRbohB gene mutant. The nucleotide sequence of the OsRbohB gene provided by the invention is as shown in SEQ ID No. 1, the OsRbohB gene mutant is obtained by performing ubiquitination modification or phosphorylation modification site mutation on the OsRbohB gene, and the nucleotide sequence of the OsRbohB gene mutant is as shown in SEQ ID No. 3 and SEQ ID No. 5. The specific embodiment of the invention proves that after the OsRbohB gene and the mutant thereof are over-expressed, the resistance of rice to rice blast can be improved, and the mutant obtained by mutation of bases at the ubiquitination modification and phosphorylation modification sites of the OsRbohB gene shows a higher resistance level. The OsRbohB gene and the mutant thereof can be introduced into other rice varieties as target genes to improve the disease resistance of the rice so as to improve the rice varieties.
Owner:INST OF PLANT PROTECTION CHINESE ACAD OF AGRI SCI

Isoindolinone and indazole compounds for the degradation of EGFR

ActiveUS12371442B2Organic active ingredientsPowder deliveryProteasome degradationDe ubiquitination
The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
Owner:C4 THERAPEUTICS INC

Application of YTHDF1 in regulation and control of tryptophan metabolism to promote formation of hepatocellular carcinoma immunosuppression microenvironment

The invention discloses a key effect and a targeted intervention strategy of YTHDF1 in regulation and control of a hepatocellular carcinoma immunosuppression microenvironment. In the tumor-associated fibroblasts, YTHDF1 enhances the translation efficiency of OTUD5 mRNA through an m6A dependency mechanism, an up-regulated deubiquitination enzyme OTUD5 is directly combined with a tryptophan metabolic rate-limiting enzyme IDO1, ubiquitination degradation of the tryptophan metabolic rate-limiting enzyme IDO1 is inhibited, tryptophan is further driven to catabolism to generate kynurenine, regulatory T cell differentiation is promoted, and an immunosuppression microenvironment is formed. Spatial transcriptomics shows that YTHDF1 + CAFs and Tregs are significantly co-localized in tumor tissues and have metabolic interaction. Based on artificial intelligence virtual screening, it is found that a natural compound hesperidin can be specifically combined with a YTH structural domain of YTHDF1, an OTUD5-IDO1 signal axis mediated by the natural compound hesperidin is blocked, and the KYN level is remarkably reduced. Animal experiments prove that the tumor inhibition rate of combined treatment of hesperidin and anti-PD-1 is increased by 40% or above compared with that of a single drug group, and synergistic interaction is achieved by inhibiting Tregs infiltration and enhancing the activity of cytotoxic T lymphocytes.
Owner:JIANGSU PROVINCE HOSPITAL (THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY)

Application of knockout NL895 E6-LIKE gene in increasing wood yield and method of knockout NL895 E6-LIKE gene

The invention discloses application of a ubiquitination gene E6-LIKE gene knockout NL895 poplar cv.' nalin895 'and a method of the ubiquitination gene E6-LIKE gene knockout NL895E6-LIKE gene knockout NL895E6-LIKE gene knockout NL895 poplar cv.' nalin895', a plant with the NL895E6-LIKE gene knockout is constructed through a CRISPR / CAS9 editing technology, the number of xylem layers in the knockout plant is remarkably increased, and the number of formed layers is also remarkably increased; the result shows that after the E6-LIKE is deleted, the stem cambium activity and xylem differentiation of the poplar are promoted, and the method has important significance on development and utilization of the poplar.
Owner:SOUTHWEST UNIV

Deubiquitinating enzyme targeting chimera compound as well as preparation method and application thereof

ActiveCN119350422ADigestive systemSteroidsChemical compoundDeubiquitinating enzyme
The invention discloses a deubiquitinating enzyme targeting chimera compound as well as a preparation method and application thereof. The structure of the deubiquitinating enzyme targeting chimera compound is as shown in formula I. According to the deubiquitinating enzyme targeting chimera compound and the preparation method thereof, an FXR ligand is modified and transformed, and a proper Linker connection site is selected; a deubiquitination enzyme ligand and an FXR ligand are connected through different flexible or rigid Linkers to synthesize DUBTACs molecules targeting FXR with different space structures, and a reasonable synthesis route is designed, so that the DUBTACs molecules have great prospects in application of an FXR stabilizer.
Owner:CHINA PHARM UNIV

PROTAC chimera for targeted degradation of ROR [gamma] t receptor and application of PROTAC chimera

The invention discloses a PROTAC chimera for targeted degradation of an ROR [gamma] t receptor and application of the PROTAC chimera, the structure of the chimera is RW-L-Re, Re is a ligand capable of being combined with E3 ubiquitin ligase, L is a linking group covalently combined with at least one Re and at least one RW, and Rw is a target protein ROR [gamma] t binding ligand and is selected from one of the following structures. A series of PROTAC chimeras capable of degrading an ROR gamma t receptor in a targeted manner are designed and synthesized for the first time, a ternary complex is formed mainly by combining a target protein ligand and an E3 ubiquitin ligase ligand with POI and E3 ligase respectively, and then the POI is labeled with a ubiquitination tag and is further degraded by proteasome. Experimental results prove that the PROTAC chimera designed by the invention has excellent ROR [gamma] t receptor degradation activity, and can be used for preparing related drugs for treating autoimmune diseases or tumors.
Owner:ZHENGZHOU UNIV

Application of original cilia CCSAP protein in preparation of medicine for treating diabetic osteoporosis

The invention discloses application of original cilia CCSAP protein in preparation of a medicine for treating diabetic osteoporosis. The original cilia CCSAP protein has a remarkable effect of treating the diabetic osteoporosis and promotes the expression of marker proteins OCN and OPN for osteogenic differentiation. According to the invention, the action mechanism of the original cilia CCSAP protein for treating the diabetic osteoporosis is defined. The cilia CCSAP protein is located at the top end and the bottom of the cilia of the osteoblast. According to the present invention, the CCSAP is subjected to overexpression, the original cilia of osteoblasts is prolonged, the hedgehog signal channel and the calcium channel are activated, the original cilia CCSAP protein interacts with the SHH and the Gli 1 protein, the original cilia CCSAP protein inhibits the Gli 1 protein ubiquitinated by the high glucose environment, the ubiquitination of the Gli 1 transcription factor is reduced, the amount of the Gli 1 protein is increased, the transcription of the osteogenic differentiation related genes OCN and OPN is activated, and the osteogenic differentiation is promoted;
Owner:CHONGQING MEDICAL UNIVERSITY

In-vitro ubiquitination screening system of E3 ubiquitin ligase Smurf1

The invention discloses an in-vitro ubiquitination screening system of E3 ubiquitin ligase Smurf1, belongs to the technical field of molecular biology and protein modification research, and provides an efficient and standardized Smurf1 in-vitro ubiquitination screening system construction method which can be used for screening E3 ubiquitin ligase Smurf1 through multi-step accurate condition control and system verification. The specificity and the repeatability of the ubiquitination reaction are ensured, and a new technical platform is provided for researching a substrate recognition mechanism and function regulation and control of Smurf1. The method can be used for high-throughput screening of Smurf1 ubiquitinated substrate proteins, and is used for mechanism research and novel drug research and development.
Owner:BEIJING INST OF TECH

SMARCA degraders and uses thereof

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI / SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and / or polybromo-1 (PB-1) protein via ubiquitination and / or degradation by compounds. The compounds are bifunctional molecules that link a cereblon-binding moiety to a ligand that binds SMARCA and / or PB1 proteins.
Owner:KYMERA THERAPEUTICS INC

Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and / or otherwise inhibited by the compounds as described herein.
Owner:DBD THERAPEUTICS LLC

A protac compound with rorγt receptor targeted degradation and uses thereof

The application discloses a PROTAC compound with RORgamma t receptor targeted degradation and purposes thereof, which is a compound with a structure shown in a general formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof. e is a ligand capable of combining with an E3 ubiquitin ligase; the L is a linking group covalently combining at least one R e and at least one R W ; the R w is a target protein RORgamma t binding ligand; the application is based on the target point of RORgamma t and the PROTAC technology, and a series of RORgamma t-PROTACs are designed and synthesized for the first time. The mechanism is that the target protein ligand and the E3 ubiquitin ligase ligand are combined with POI and E3 ligase respectively, so as to form a ternary complex of "POI-PROTAC-E3 ligase". Then, the POI is marked with a ubiquitination label, and is degraded by a proteasome. The advantages of RORgamma t-PROTACs mainly include targeting of "undruggable proteins", small dosage, low toxicity, and difficulty in drug resistance. W -L-R e (I)
Owner:ZHENGZHOU UNIV

Use of diphenylacetonitrile compounds and protein target hydrolyzable chimeric compounds

The application relates to the field of medicinal chemistry and provides a use of a diphenylacetonitrile compound and a protein-targeting hydrolytic chimeric compound. The application finds that a diphenylacetonitrile compound shown in formula (I) directly interacts with FEM1B, thereby serving as an inhibitor of a human E3 ubiquitin ligase substrate recognition receptor FEM1B. The application also provides a compound shown in formula (II), and the compound shown in formula (II) is a protein-targeting hydrolytic chimeric (PROTAC) drug, wherein Q2 is a target protein ligand molecule, Q1 is a FEM1B inhibitor, Q2 is combined with a target protein, thereby inducing E3 ligase FEM1B combined with Q1 to approach the target protein, leading to ubiquitination and degradation of the target protein. Experimental results show that the PROTAC drug shown in formula (II) provided by the application can specifically degrade a target protein in cells. Formula (I); formula (II).
Owner:UNIV OF SCI & TECH OF CHINA +1

FBXO21 MEDIATED P85a UBIQUITYLATION AS A THERAPEUTIC TARGET IN CANCER

PCT designated stageWO2026072967A1Organic chemistryAntineoplastic agentsGastrointestinal cancerChronic myeloproliferative disorders
The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:UNIV OF UTAH RES FOUND +1

Novel protein targeted degradation technology based on artificially modified NEL structural domain

The invention provides a recombinant protein containing an artificially modified NEL structural domain and application of the recombinant protein in targeted degradation of protein. Experimental results show that the recombinant protein can simply and efficiently realize controllable adjustment of the target protein level in cells, and has better stability by reducing the self-ubiquitination level. The invention also provides a construction method of the recombinant protein and an application of the recombinant protein in the process of inhibiting cell autophagy.
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI

Engineered car-t cells secreting membrane protein degraders and uses thereof

PendingCN122404573AAntigenLysosome
This invention discloses an enhanced CAR-T cell (CARTAC) capable of secreting a targeted membrane protein degrader and its applications. While retaining specific killing function, this cell can expand locally in tumors and continuously secrete the bispecific adaptor molecule scTAC. scTAC can recruit E3 ubiquitin ligases, mediate ubiquitination of tumor cell surface membrane proteins (such as PD-L1), and achieve targeted degradation via the lysosomal pathway, effectively reversing the immunosuppressive microenvironment, overcoming antigen heterogeneity, and eliminating antigen-negative tumor cells through the bystander effect. This invention also utilizes the efficient endocytosis properties of EGFR to design scTAC-dual, which can further enhance degradation efficiency. In various lung cancer mouse models, CARTAC-dual exhibited excellent tumor infiltration capacity, low exhaustion levels, and sustained antitumor activity, without systemic toxicity. This invention integrates the targeted killing and protein degradation delivery functions of CAR-T cells, not only enhancing the control effect on solid tumors but also possessing target scalability, making it suitable for the universal upgrading of various CAR-T products.
Owner:WESTLAKE UNIV

Novel GSPT protein degrader and application thereof

The present disclosure relates to novel compounds that act as modulators of cereblon (CRBN). The compounds promote CRBN-mediated ubiquitination and proteasomal degradation of oncogenic proteins such as GSPT1 and MYC, thereby suppressing abnormal cell growth. Pharmaceutical compositions containing the compounds and methods of using the compositions for the treatment of cancers, particularly solid tumors, are also provided.
Owner:GENOSCO INC

Application of hederagenin in preparation of medicine serving as SKP2 degradation agent, PROTAC compound for targeted degradation of SKP2 as well as preparation method and application of PROTAC compound

The invention provides an application of hederagenin in preparation of a medicine used as an SKP2 degradation agent, and particularly provides an application of hederagenin in preparation of a medicine used as an SKP2 degradation agent. The invention also provides a PROTAC compound, which comprises a target protein POI ligand, an E3 ubiquitin ligase ligand and a linking chain Linker, the general formula of the ligand-Linker-E3 ligase ligand is as follows: a POI ligand-Linker-E3 ligase ligand. The invention also provides a preparation method and application of the PROTAC compound. The PROTAC design based on HED improves the tumor tissue targeting property, and shows low toxicity in an in-vivo experiment. The invention provides a novel SKP2 (SKP2) degradation agent. The degradation agent is expected to be capable of efficiently inducing ubiquitination degradation of SKP2 protein, and a treatment strategy with higher potential and clinical application prospect is provided for overcoming the limitation of the prior art by enhancing the specific killing capability on SKP2 high-expression tumor cells and verifying the remarkable tumor inhibition effect and good safety of the degradation agent in an animal model.
Owner:THE AFFILIATED HOSPITAL OF TRADITIONAL CHINESE MEDICAL TO SOUTHWEST MEDICAL UNIV